On December 19, 2025, Nanjing Zijin Biomedical Industry Investment Fund Partnership (Limited Partnership) (hereinafter referred to as the "Biomedical Mother Fund") held the third meeting of the Sub-Fund Investment Decision-Making Committee, which reviewed and approved the sub-funds to be participated in by the Biomedical Mother Fund. The details are as follows:

The fund has a target size of RMB 500 million, is planned to be registered and located in Nanjing Jiangbei New Area, with an 8-year term. It will mainly invest in fields such as medical devices, high-end pharmaceuticals, biotechnology, medical and health services, etc.

In accordance with the requirements specified in the announcement for the selection of proposed sub-fund managers of the Biomedical Mother Fund, through the processes of institutional application, preliminary document review, due diligence, investment decision-making, etc., the proposed sub-funds to be participated in (attached below) are now publicly announced. The public announcement period is 5 working days, from December 22, 2025 to December 26, 2025.

Any unit or individual who has objections to the announced results may submit a written objection during the public announcement period, along with the reasons for the objection and relevant supporting materials. Objections submitted in the name of a unit must be stamped with the unit's official seal. Objections submitted in the name of an individual must include the individual's real name, unit, contact address, contact information, etc., and be signed by the individual. To ensure that objection handling is objective, fair, just and timely, anonymous objections or those submitted after the public announcement period will not be accepted.

Contact Person: Ms. GongContact Telephone: +86 25-86596507Contact Email: selection@njicg.comContact Address: 41F, Building 4, Financial City, Jianye District, Nanjing, Jiangsu Province

Attachment: List of Proposed Sub-Funds to be Participated in by the Biomedical Mother Fund